Valneva Stock Under Pressure, Drops Nearly 2%
The Lyon-based biotech specializing in vaccines declines during the session, amidst a slightly bullish SBF 120. The stock continues to operate in a fragile technical zone, after a quarter marked by a massive price decline and a reorganization. The annual general meeting is scheduled for today.
The stock stalls between support at €2.26 and the 50-day moving average
Valneva's stock is down 1.95% at €2.5610 midday, while the SBF 120 gains 0.13%. The stock remains in a medium-term bearish configuration, with its price below its 50-day moving average (MA50) at €2.69 (a gap of -4.80%) and well below the 200-day moving average (MA200) at €3.80 (a gap of -32.61%). In the short term, however, the session is playing out above the 20-day moving average (MA20) at €2.51, which keeps the stock in the breathing zone opened by last week's rebound (+3.48% over seven days). The RSI at 46 indicates a neutral momentum, with no clear reversal signal. The technical support at €2.26, already tested in mid-May following the capital increase of 84 million euros, remains the lower reference point; the resistance at €2.74 marks the upper limit of the corridor. The stock is ranked low in the SBF 120, in an index otherwise driven by Vusion and Atos.
An Annual General Meeting Today and a Scientific Calendar in June
The financial calendar schedules the annual general meeting for June 1st, followed by Valneva's participation in the Northern European Conference on Travel Medicine (NECTM10) on June 3rd. The laboratory also announced on May 29 its participation in three investor conferences in June, where the management is set to present its commercial strategy and portfolio of candidates, including LB6V against Lyme disease co-developed with Pfizer. Against this backdrop, the stock performance remains weighed down by the first quarter results published on May 13: revenue down 37%, net loss of 32.1 million euros and a reorganization plan aiming to reduce operational expenses by 25 to 35% and global workforce by 10 to 15%. During this announcement, the company adjusted its 2026 revenue guidance to a range of 135 to 150 million euros, focusing its resources on key strategic projects. Over three months, the stock has still lost 45.86%. The next market event remains the NECTM10 conference on June 3, which could provide factual updates on the progress of the vaccine portfolio.
